Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations

Enrico P Spugnini¹ , Stefania Crispi² , Alessandra Scarabello³ , Giovanni Caruso⁴ , Gennaro Citro¹ and Alfonso Baldi⁴

¹S.A.F.U. Department, Regina Elena Cancer Institute –, Rome –, Italy

²Gene Expression Core, – Human Molecular Genetics Laboratory, Institute of Genetics and Biophisycs, CNR, Naples, Italy

³Istituto Dermatologico San Gallicano, Rome, Italy

⁴Department of Biochemistry, section of Pathology, Second University of Naples, Italy

author email corresponding author email

Journal of Experimental & Clinical Cancer Research 2008, 27:6doi:10.1186/1756-9966-27-6


Published:	19 May 2008

Abstract

Malignant Mesothelioma is an uncommon and very aggressive tumor that accounts for 1% of all the deaths secondary to malignancy in humans. Interestingly, this neoplasm has been occasionally described in companion animals as well. Aim of this study was the preclinical evaluation of the combination of piroxicam with platinum-based intracavitary chemotherapy in pets. Three companion animals have been treated in a three years period with this combination. Diagnosis was obtained by ultrasonographic exam of the body cavities that evidenced thickening of the mesothelium. A surgical biopsy further substantiated the diagnosis. After drainage of the malignant effusion from the affected cavity, the patients received four cycles of intracavitary CDDP at the dose of 50 mg/m²every three weeks if dogs or four cycles of intracavitary carboplatin at the dose of 180 mg/m²(every 3 weeks) if cats, coupled with daily administration of piroxicam at the dose of 0.3 mg/kg. The therapy was able to arrest the effusion in all patients for variable remission times: one dog is still in remission after 3 years, one dog died of progressive disease after 8 months and one cat died due to progressive neoplastic growth after six months, when the patient developed a mesothelial cuirass. The combination showed remarkable efficacy at controlling the malignant effusion secondary to MM in our patients and warrants further investigations.